Literature DB >> 3511649

The role of renal hemodynamics in the antihypertensive effect of captopril.

K Ando, T Fujita, Y Ito, H Noda, K Yamashita.   

Abstract

To evaluate the role of regional hemodynamics in mediating the long-term depressor effect of the converting enzyme inhibitor, captopril, at a low dose (37.5 mg/day), for 2 weeks, its systemic, renal, and forearm circulatory actions were determined in 12 patients with mild to moderate essential hypertension. After administration of captopril, there was a significant decline in mean blood pressure (average -12.1 +/- 1.9%) accompanied by a decrease in systemic vascular resistance (-9.1 +/- 3.3%), but cardiac output did not change. Although forearm vascular resistance was not altered, renal vascular resistance decreased considerably (-17.1 +/- 5.0%). Moreover, there was a highly significant (r = 0.891) correlation between the changes in mean blood pressure and renal vascular resistance. Plasma renin activity increased after therapy as plasma aldosterone decreased, while plasma norepinephrine slightly increased. The change in renal vascular resistance significantly (r = -0.617) correlated with the pretreatment level of plasma renin activity. These findings suggest that suppression of the renin-angiotensin system in essential hypertension induces selective vasodilation in the renal vasculature, which may play an important role in the long-term antihypertensive effect of the converting enzyme inhibitor. This renal vasodilator action appears to be the feature that distinguishes the converting enzyme inhibitor from conventional vasodilator drugs.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3511649     DOI: 10.1016/0002-8703(86)90152-3

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  9 in total

1.  Effects of ketanserin on systemic and regional haemodynamics in patients with essential hypertension.

Authors:  Y Ito; M Isaka; H Noda; Y Sato; T Fujita
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 2.  Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  R N Brogden; P A Todd; E M Sorkin
Journal:  Drugs       Date:  1988-11       Impact factor: 9.546

3.  Vasodilatory actions of alpha-human atrial natriuretic peptide and high Ca2+ effects in normal man.

Authors:  T Fujita; Y Ito; H Noda; Y Sato; K Ando; K Kangawa; H Matsuo
Journal:  J Clin Invest       Date:  1987-09       Impact factor: 14.808

4.  Effects of captopril and nadolol on renal hemodynamics in patients with essential hypertension.

Authors:  Z H Zhu; R An; Y X Zhang; P L Gong; H Chen; F D Zen
Journal:  J Tongji Med Univ       Date:  1994

Review 5.  Renal effects of antihypertensive drugs.

Authors:  W A Schlueter; D C Batlle
Journal:  Drugs       Date:  1989-06       Impact factor: 9.546

Review 6.  Acute and chronic effects of angiotensin converting enzyme inhibitors on the essential hypertensive kidney.

Authors:  G P Reams; J H Bauer
Journal:  Cardiovasc Drugs Ther       Date:  1990-02       Impact factor: 3.727

Review 7.  Treatment of hypertension in black patients with angiotensin-converting enzyme inhibitors.

Authors:  N B Shulman
Journal:  J Natl Med Assoc       Date:  1988-03       Impact factor: 1.798

Review 8.  How Do Antihypertensive Drugs Work? Insights from Studies of the Renal Regulation of Arterial Blood Pressure.

Authors:  Holly Digne-Malcolm; Matthew C Frise; Keith L Dorrington
Journal:  Front Physiol       Date:  2016-07-29       Impact factor: 4.566

9.  Highly potent antioxidant Olea europaea L. leaf extract affects carotid and renal haemodynamics in experimental hypertension: The role of oleuropein.

Authors:  Milan Ivanov; Una-Jovana Vajic; Nevena Mihailovic-Stanojevic; Zoran Miloradovic; Djurdjica Jovovic; Jelica Grujic-Milanovic; Danijela Karanovic; Dragana Dekanski
Journal:  EXCLI J       Date:  2018-01-04       Impact factor: 4.068

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.